Clinical Trial: Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827430) titled 'Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD' on Sept. 14.

Brief Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally. The progression of liver fibrosis (scarring) represents the most critical determinant of long-term liver-related morbidity and mortality in these patients. Thyroid hormones play an essential role in hepatic lipid metabolism, and thyroid dysfunction, specifically overt and subclinical hypothyroidism, has been implicated in the deve...